Cladribine
ATC L04AA40 · 11 markets · 51 records
AU 16 records · 5 strengths
- 10 mgtabletCLADRITABCLADRITAB cladribine 10mg tablet blister pack、Mavenclad、MAVENCLAD cladribine 10mg tablet blister pack
- 10 mg/10 mLinjectionLEUSTATIN
- 10 mg/5 mLinjectionLITAK
- 2 mg/mLinjectionLITAK cladribine 10mg/5mL injection vial
Records without a stated strength · 1 CLADRITAB、LEUSTATIN、LITAK、Mavenclad
US 7 records · 2 strengths
- 10 mgtabletMavenclad__no_trade__
- 1 mginjectionNo trade name
GB 5 records · 3 strengths
- 10 mgtabletMavenclad__no_trade__
- 10 mg/10 mLinjectionLeustat 10mg/10ml solution for infusion vials
- 10 mg/5 mLinjectionLitak 10mg/5ml solution for injection vials
CA 5 records · 2 strengths
- 10 mgtabletAPO-CLADRIBINEAURO-CLADRIBINE、Mavenclad
- 1 mgliquidCladribine
ES 4 records · 3 strengths
EU 3 records · 1 strengths
EU centralised authorisation (EMA) — Authorised at EU level — not a record of sale in any single country. The EU register carries no strength, dosage form or pack size.
Records without a stated strength · 1 LITAK、Mavenclad、Movectro
CN 2 records · 1 strengths
- 10 mg/10 mLinjection艾博定克拉屈滨__mah__:四川汇宇制药股份有限公司
TW 2 records · 2 strengths
- 10 mgtabletMavenclad瑪威克錠10毫克
Records without a stated strength · 1 LEUSTATIN、祿斯得停注射劑
SG 1 records · 1 strengths
- 10 mgtabletMavenclad
HK 1 records · 1 strengths
Records without a stated strength · 1 Mavenclad
| Strength / form / release | US | GB | CA | AU | SG | CN | ES | TW | HK | EU |
|---|---|---|---|---|---|---|---|---|---|---|
| 10 mg tablet | No trade name Mavenclad | No trade name Mavenclad | APO-CLADRIBINE AURO-CLADRIBINE Mavenclad | CLADRITAB CLADRITAB cladribine 10mg tablet blister pack Mavenclad+1MAVENCLAD cladribine 10mg tablet blister pack | Mavenclad | Mavenclad | Mavenclad 瑪威克錠10毫克 | |||
| 10 mg/10 mL injection | Leustat 10mg/10ml solution for infusion vials | LEUSTATIN | Manufacturer: 四川汇宇制药股份有限公司 艾博定克拉屈滨 | LEUSTATIN | ||||||
| 10 mg/5 mL injection | Litak 10mg/5ml solution for injection vials | LITAK | ||||||||
| 1 mg liquid | Cladribine | |||||||||
| 2 mg injection | LITAK | |||||||||
| 2 mg/mL injection | LITAK cladribine 10mg/5mL injection vial | |||||||||
| 1 mg injection | No trade name | |||||||||
unknown | CLADRITAB LEUSTATIN LITAK | Mavenclad | LITAK Mavenclad Movectro | |||||||
injection | LEUSTATIN 祿斯得停注射劑 |
Scroll horizontally for more markets →
Each country column shows the locally registered trade names — not translations.
2 more strength/form rows are recorded only in ES · TW and are not shown in this table. Hay 2 filas de concentración/forma registradas solo en ES · TW que no se muestran en esta tabla. 另有 2 个规格/剂型仅在 ES · TW 有记录(未在本表显示)。 另有 2 個規格/劑型僅在 ES · TW 有記錄(未在本表顯示)。
“not disclosed” means the source does not publish the strength — it does not mean the product has none.
Hong Kong records are name/ingredient-level only: no strength, dosage form or registration status; on the register does not prove current supply.
Australia ARTG data has no registration-status column, so status is shown as unknown; being on the register does not mean currently marketed.
EU centralised authorisation (EMA) — Authorised at EU level — not a record of sale in any single country. The EU register carries no strength, dosage form or pack size.
Discontinued, withdrawn or unverified-status products are hidden by default; Hong Kong and Australia records are shown as exceptions.